![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})
Abstract
Background: There is a critical need to develop effective new strategies for the management of patients with advanced epithelial ovarian cancer. Objective: The purpose of this manuscript is to discuss the rationale for, and initial clinical results of, attempts to interfere with the process of tumor angiogenesis as a novel treatment paradigm in ovarian cancer. Results/ conclusion: Phase II clinical trial data provide strong support for the suggestion that antiangiogenic agents have the potential to play a major therapeutic role in this difficult malignancy. It is reasonable to acknowledge that the pending results of several ongoing evidence-based randomized Phase III trials that directly explore the clinical utility of this strategy may substantially alter the current standard management approaches in advanced ovarian cancer.